SCHEMBL16091748

SCHEMBL16091748

CCCc1cc(C)c2ccoc2c1N

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 1/20 0.37
▸ TLR8 Q9NR97 2/20 0.35
▸ KDM4E B2RXH2 7/20 0.34
▸ ALDH1A1 P00352 6/20 0.34
▸ TSHR P16473 3/20 0.34
▸ HSD17B10 Q99714 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ HPGD P15428 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ SLC5A2 P31639 1/20 0.32
▸ ALOX5 P09917 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ KCNA2 P16389 1/20 0.31
▸ SKP2 Q13309 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16091762 0.87 TLR8 (0.35) NOS2TLR8KDM4EALDH1A1TSHR
SCHEMBL15629834 0.87 GAA (0.37) NOS2KDM4EALDH1A1HSD17B10GAA
SCHEMBL16091759 0.77 ESR1 (0.34) TLR8KDM4EALDH1A1TSHRHSD17B10
SCHEMBL15629833 0.73 HTT (0.35) NOS2ALDH1A1HSD17B10GAAGFER
SCHEMBL16715969 0.73 KCNA2 (0.36) NOS2KDM4EALDH1A1HPGDPOLB
SCHEMBL16091765 0.72 KDM4E (0.37) NOS2TLR8KDM4EALDH1A1TSHR
SCHEMBL16091776 0.70 TLR8 (0.34) NOS2TLR8KDM4EALDH1A1TSHR
SCHEMBL16091764 0.68 P2RX7 (0.33) NOS2KDM4EALDH1A1HSD17B10GAA
SCHEMBL3801326 0.67 SKP2 (0.37) NOS2KDM4EALDH1A1TSHRHSD17B10
SCHEMBL16572668 0.66 ALDH1A1 (0.36) NOS2KDM4EALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9340521-B2 Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives GREEN CROSS CORPORATION (KR) 2016-05-17 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES GREEN CROSS CORPORATION (KR) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 NOS2 2849/4885TLR8 1145/4885KDM4E 1804/4885
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES SLC5A2, SLC5A1, SLC10A2 NOS2 2904/4885TLR8 2460/4885KDM4E 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback